US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(CSE:
MBIO
)
0.1400
UNCHANGED
Delayed Quote
Updated: 12:21 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MBIO
< Previous
1
2
3
Next >
MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients
October 28, 2023
Via
ACCESSWIRE
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
October 26, 2023
Via
ACCESSWIRE
MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
October 24, 2023
Via
ACCESSWIRE
Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials
October 05, 2023
Via
ACCESSWIRE
Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
September 14, 2023
Via
ACCESSWIRE
MindBio Therapeutics Announces Major Genetic Discovery in Microdosing Research
September 05, 2023
Via
ACCESSWIRE
Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression
August 24, 2023
Via
ACCESSWIRE
Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials
August 18, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
